Investor Lawsuit Targets BioAge Labs Following Disrupted Drug Trial and Stock Plunge
New York — A prominent securities law firm, Bleichmar Fonti & Auld LLP, has recently initiated a lawsuit against BioAge Labs, Inc., a company listed on NASDAQ under the ticker BIOA, along with some of its top executives. The legal action alleges potential breaches of federal securities laws linked to the company’s initial public offering. As part of the case, which is filed under the docket Soto v. BioAge Labs, Inc., et al., No. 25-cv-196, plaintiffs must file their petitions by March 10, 2025, to be considered as lead plaintiffs. The filed complaint highlights issues … Read more